Revance Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss
The total revenue of RVNC for the last quarter is 51.94 M USD, and it's 25.59% lower compared to the previous quarter. The net income of Q1 24 is -53.15 M USD.